These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 26318867)

  • 1. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence.
    Federico A; Dallio M; Godos J; Loguercio C; Salomone F
    Transl Res; 2016 Jan; 167(1):116-24. PubMed ID: 26318867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.
    Xue L; He J; Gao N; Lu X; Li M; Wu X; Liu Z; Jin Y; Liu J; Xu J; Geng Y
    Sci Rep; 2017 Mar; 7():45176. PubMed ID: 28349964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis.
    Dornas W; Lagente V
    Pharmacol Res; 2019 Mar; 141():418-428. PubMed ID: 30658094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis.
    Qamar AA
    J Clin Gastroenterol; 2015; 49 Suppl 1():S28-32. PubMed ID: 26447961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal microbiota and nonalcoholic steatohepatitis.
    Brandl K; Schnabl B
    Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
    Li DY; Yang M; Edwards S; Ye SQ
    JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis.
    Ferolla SM; Couto CA; Costa-Silva L; Armiliato GN; Pereira CA; Martins FS; Ferrari Mde L; Vilela EG; Torres HO; Cunha AS; Ferrari TC
    Nutrients; 2016 Jun; 8(7):. PubMed ID: 27367724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
    de Faria Ghetti F; Oliveira DG; de Oliveira JM; de Castro Ferreira LEVV; Cesar DE; Moreira APB
    Eur J Nutr; 2018 Apr; 57(3):861-876. PubMed ID: 28875318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
    Fianchi F; Liguori A; Gasbarrini A; Grieco A; Miele L
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of gut-liver-immune axis in the pathogenesis of nonalcoholic steatohepatitis].
    Shao L; Song Y; Shi JP
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):505-509. PubMed ID: 34225424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiology and pathophysiology of liver lipid metabolism.
    Ponziani FR; Pecere S; Gasbarrini A; Ojetti V
    Expert Rev Gastroenterol Hepatol; 2015; 9(8):1055-67. PubMed ID: 26070860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.